Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gallopamil binding to human serum proteins.

D R Rutledge1, J A Pieper

  • 1Department of Pharmacy Practice, College of Pharmacy, Wayne State University, Detroit, Michigan.

European Journal of Clinical Pharmacology
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacologic interventions for coronary artery disease and risk factors. Introduction.

Pharmacotherapy·2001
Same author

Management of coronary heart disease risk factors and progression with calcium channel blockers.

Pharmacotherapy·2001
Same author

Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.

Journal of clinical pharmacology·2001
Same author

Clinical pharmacokinetics of fluvastatin.

Clinical pharmacokinetics·2001
Same author

Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.

Journal of clinical pharmacology·2001
Same author

Applying managed care performance measures in community pharmacy-based outcomes research.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·1999

Gallopamil binds to human serum proteins, primarily alpha-1 acid glycoprotein and albumin. Factors like drug interactions and pH significantly influence gallopamil

Area of Science:

  • Pharmacokinetics
  • Biochemistry
  • Drug Metabolism

Background:

  • Understanding drug binding to serum proteins is crucial for predicting drug efficacy and toxicity.
  • Gallopamil is a cardiovascular drug whose interactions with plasma proteins require detailed investigation.

Purpose of the Study:

  • To determine the extent and variability of gallopamil binding to human serum proteins.
  • To identify the primary binding proteins and factors influencing gallopamil's free fraction.

Main Methods:

  • Equilibrium dialysis was employed to measure gallopamil binding in healthy volunteer serum, human serum albumin, and alpha-1 acid glycoprotein (AAG).
  • Nonlinear regression analysis was used to characterize binding sites.
  • Gallopamil free fraction was assessed across various concentrations, pH levels, and in the presence of other drugs.

Related Experiment Videos

Main Results:

  • Gallopamil exhibits two classes of binding sites in human serum, with affinities consistent with AAG and albumin.
  • Alpha-1 acid glycoprotein (AAG) was identified as the high-affinity, low-capacity binding site, while albumin served as the low-affinity, high-capacity site.
  • Gallopamil's free fraction was influenced by AAG concentration, serum pH, and co-administered drugs like verapamil and propranolol.

Conclusions:

  • Alpha-1 acid glycoprotein and albumin are the principal binding proteins for gallopamil in human serum.
  • Variability in gallopamil binding is attributed to changes in AAG levels, pH, and interactions with other drugs.
  • These findings are vital for optimizing gallopamil dosing and predicting its clinical behavior.